Efficacy and Safety of FP-1201-lyo (Interferon Beta-1a) in Patients Having Acute Respiratory Distress Syndrome (ARDS)
Status:
Terminated
Trial end date:
2018-05-23
Target enrollment:
Participant gender:
Summary
In this study effectiveness and safety of a new drug FP-1201-lyo (recombinant human
interferon beta-1a) is compared to placebo. Investigation is conducted with patients who have
acute respiratory distress syndrome (ARDS). The new drug is expected to reduce the time which
a patient need to be on the ventilator and improve patient's chances of survival. Currently
there are no approved drugs for treating moderate or severe ARDS patients.